SC
NVO

Swan Capital’s Novo Nordisk NVO Stock Holding History

Swan Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.49K Hold
95
– – ﹤0.01% 300
2025
Q4 		$4.83K Sell
95
-25
-21% -$1.28K ﹤0.01% 240
2025
Q3 		$6.66K Buy
120
+60
+100% +$3.51K ﹤0.01% 194
2025
Q2 		$4.14K Buy
+60
New +$4.08K ﹤0.01% 254
2024
Q4 		– Sell
-10
Closed -$1.19K – 410
2024
Q3 		$1.19K Buy
+10
New +$1.33K ﹤0.01% 257

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Swan Capital's NVO Position: Q1 2026 in Review

Swan Capital held its Novo Nordisk (NVO) position steady in Q1 2026 at 95 shares worth $3.49K. The position accounts for ﹤0.01% of the portfolio, ranked #300.

Swan Capital first reported a position in NVO in Q3 2024 and has held it in 5 quarters since. The position peaked at $6.66K in Q3 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Swan Capital held 95 shares of Novo Nordisk worth $3.49K as of Q1 2026.
  • Swan Capital left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up ﹤0.01% of Swan Capital's portfolio in Q1 2026, its #300 holding.
  • Swan Capital first reported a position in Novo Nordisk in Q3 2024 and has held it in 5 quarters since.
  • Swan Capital's Novo Nordisk position peaked at $6.66K in Q3 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Swan Capital's 13F filing for Q1 2026, filed 14 May 2026.